Colistimethate sodium (Colobreathe®)

Assessment Status Rapid Review complete
Drug Colistimethate sodium
Brand Colobreathe®
Indication For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.
Assessment Process
Rapid review commissioned 07/06/2013
Rapid review completed 28/06/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Not Recommended